

# Julie V Decock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4506613/publications.pdf>

Version: 2024-02-01

50  
papers

2,011  
citations

304743

22  
h-index

265206

42  
g-index

53  
all docs

53  
docs citations

53  
times ranked

3398  
citing authors

#	ARTICLE	IF	CITATIONS
1	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. <i>Frontiers in Immunology</i> , 2018, 9, 947.	4.8	261
2	Matrix metalloproteinases: protective roles in cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1254-1265.	3.6	160
3	Immune checkpoints in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 65, 1-12.	9.6	146
4	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2229.	4.1	105
5	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 600573.	2.8	100
6	Association of Matrix Metalloproteinase-8 Gene Variation with Breast Cancer Prognosis. <i>Cancer Research</i> , 2007, 67, 10214-10221.	0.9	85
7	The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1861.	3.0	83
8	Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?. <i>Cancers</i> , 2019, 11, 984.	3.7	78
9	Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 181-187.	2.5	76
10	The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1940.	4.8	66
11	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
12	Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis. <i>BMC Cancer</i> , 2008, 8, 77.	2.6	55
13	TGF- $\beta$ 2-Elicited Induction of Tissue Inhibitor of Metalloproteinases (TIMP)-3 Expression in Fibroblasts Involves Complex Interplay between Smad3, p38 $\beta$ , and ERK1/2. <i>PLoS ONE</i> , 2013, 8, e57474.	2.5	55
14	Matrix Metalloproteinase 8 (Collagenase 2) Induces the Expression of Interleukins 6 and 8 in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 16282-16294.	3.4	52
15	Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. <i>Clinical Genetics</i> , 2008, 73, 197-211.	2.0	50
16	Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs 15. <i>International Journal of Cancer</i> , 2015, 136, E14-26.	5.1	46
17	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 429-445.	2.6	45
18	PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 9.	4.4	43

#	ARTICLE	IF	CITATIONS
19	Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. <i>International Journal of Biological Markers</i> , 2008, 23, 161-168.	1.8	36
20	P54 Triple positive (ER+/PR+/HER-2+) breast carcinomas occur at a younger age than all other ER/PR/HER-2 breast cancer phenotypes. <i>Breast</i> , 2007, 16, S27-S28.	2.2	35
21	Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice. <i>Breast Cancer Research</i> , 2015, 17, 38.	5.0	35
22	Proteases and metastasis: clinical relevance nowadays?. <i>Current Opinion in Oncology</i> , 2005, 17, 545-550.	2.4	33
23	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. <i>Nature Communications</i> , 2022, 13, 946.	12.8	30
24	Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. <i>Breast Cancer Research</i> , 2017, 19, 33.	5.0	29
25	Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 598626.	2.8	26
26	Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis. <i>Frontiers in Oncology</i> , 2021, 11, 681377.	2.8	25
27	Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 449-463.	4.2	20
28	Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas. <i>Disease Markers</i> , 2007, 23, 189-196.	1.3	19
29	Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 349-358.	2.5	18
30	Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological Variables. <i>Clinical and Experimental Metastasis</i> , 2005, 22, 495-502.	3.3	17
31	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
32	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. <i>F1000Research</i> , 2017, 6, 296.	1.6	14
33	Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells. <i>Frontiers in Oncology</i> , 2013, 3, 239.	2.8	13
34	Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10376-10388.	3.6	13
35	Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 153-159.	2.5	11
36	Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry. <i>Npj Breast Cancer</i> , 2021, 7, 10.	5.2	11

#	ARTICLE	IF	CITATIONS
37	Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. <i>Molecular Oncology</i> , 2022, 16, 885-903.	4.6	11
38	Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2007, 619, 104-112.	1.0	6
39	ADAMTS15 metalloproteinase inhibits breast cancer cell migration. <i>Breast Cancer Research</i> , 2010, 12, .	5.0	5
40	Short-Term Prognostic Index for Breast Cancer: NPI or Lpi. <i>Pathology Research International</i> , 2011, 2011, 1-7.	1.4	4
41	Association of MMP8 gene variation with breast cancer prognosis. <i>Breast Cancer Research</i> , 2008, 10, .	5.0	2
42	Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis. <i>Breast Cancer Research</i> , 2008, 10, .	5.0	2
43	Matrix metalloproteinases: a dual role in breast cancer?. <i>Breast Cancer Management</i> , 2013, 2, 353-356.	0.2	1
44	PRAME, cell migration and invasion of triple negative breast cancer cells. <i>Annals of Oncology</i> , 2017, 28, xi26.	1.2	1
45	How Accurate Is the Antiprimer Quenching-Based Real-Time PCR for Detection of Her2/neu in Clinical Cancer Samples?. <i>Clinical Chemistry</i> , 2006, 52, 1438-1439.	3.2	0
46	P52 The axillary lymph node status (ALNS) of breast cancers by combined ER, PR and HER-2 expression: Triple positive tumours are more likely lymph node positive. <i>Breast</i> , 2007, 16, S27.	2.2	0
47	Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?. , 2015, 3, P381.		0
48	Clinical relevance of plasma matrix metalloproteinase-2 levels in primary invasive breast cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 9680-9680.	1.6	0
49	Metalloproteinase-dependent And -independent Processes Contribute To Inhibition Of Breast Cancer Cell Migration, Angiogenesis And Liver Metastasis By A Disintegrin And Metalloproteinase With Thrombospondin Motifs-15.. , 2014, , .		0
50	579â€¦Lactate dehydrogenase C-associated molecular networks predict enhanced tumor growth and impaired immune response in breast cancer. , 2020, , .		0